Research
Energy balance
R-ESG offered higher total body weight loss (TBWL%) than GLP1/GIP-RA at 3 months (11.2% vs. 4.3%, p < .001), 6 months (13.5% vs. 6.8%, p < .001), and 12 months (13.4% vs. 9.2%, p = .07).
Practitioners may consider R-ESG as a more effective option for weight loss in patients experiencing weight recidivism after sleeve gastrectomy.
StrongSupportsmedium confidence
R-ESG offered higher TBWL% than GLP1/GIP-RA at 3 (11.2% vs. 4.3%, p < .001), 6 (13.5% vs. 6.8%, p < .001) and 12 months (13.4% vs. 9.2%, p = .07).
Why this rating
The study is a retrospective analysis with a significant sample size.
Source
Revisional endoscopic sleeve gastroplasty versus semaglutide and tirzepatide for weight recidivism after sleeve gastrectomy
Firas Bahdi et al. · Clinical Obesity · 2025
cohort · n=90Cited 9×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →